Galegenimab

DRUG2 trials

Sponsors

Genentech, Inc.

Conditions

Geographic AtrophyMacular Degeneration, Age-Related

Phase 2

A Study Assessing the Safety, Tolerability, and Efficacy of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration (AMD)

TerminatedNCT03972709

Genentech, Inc.Geographic Atrophy, Macular Degeneration, Age-Related

Start: 2019-06-03End: 2022-10-27Updated: 2024-03-27

A Study Assessing the Long-Term Safety and Tolerability of Galegenimab (FHTR2163) in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration

TerminatedNCT04607148

Genentech, Inc.Geographic Atrophy, Macular Degeneration, Age-Related

Start: 2020-11-16End: 2022-11-14Updated: 2023-10-16